Clinical trial

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

NCT05073692

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2021-07-01

PhaseN/A

Study timeline

Study start (actual)2021-07-01Date precision: day

Registry last updated2025-11-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Cardiovascular Diseasesunresolved

Interventions

SUDRUG

DPP4DRUG

SGLT2i or GLP-1RADRUG

Linagliptin (DPP4)DRUG

Exenatide (GLP-1RA)DRUG

Liraglutide (GLP-1RA)DRUG

Empagliflozin (SGLT2i)DRUG

Glimepiride (SU)DRUG

Glipizide (SU)DRUG

Glimepiride (SU) or Glipizide (SU)DRUG

SU or DPP4 (excluding saxagliptin and alogliptin)DRUG

Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)DRUG

Sponsors & collaborators

Kaiser Permanentelead sponsor

Geisinger Cliniccollaborator

Henry Ford Health Systemcollaborator

HealthPartners Institutecollaborator

Patient-Centered Outcomes Research Institutecollaborator

Mapped research locations

DetroitMichigan, United States1 HonoluluHawaii, United States1 PasadenaCalifornia, United States1 DanvillePennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05073692 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.